[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index and the Health Care",
    "url": "https://finnhub.io/api/news?id=a13b75d2b8677b4e342a5133272821794d1f7ae657498da115f73131042ca6ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757451145,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 136689248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index and the Health Care",
      "url": "https://finnhub.io/api/news?id=a13b75d2b8677b4e342a5133272821794d1f7ae657498da115f73131042ca6ba"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise in Afternoon Trading",
    "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the Health Care Selec",
    "url": "https://finnhub.io/api/news?id=c8730000d8d7d1c93b37277d7e7525b7f0ad393d4f20abd416f85ce4f4f4360b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757443921,
      "headline": "Sector Update: Health Care Stocks Rise in Afternoon Trading",
      "id": 136689249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the Health Care Selec",
      "url": "https://finnhub.io/api/news?id=c8730000d8d7d1c93b37277d7e7525b7f0ad393d4f20abd416f85ce4f4f4360b"
    }
  },
  {
    "ts": null,
    "headline": "Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System",
    "summary": "MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.",
    "url": "https://finnhub.io/api/news?id=199769a42edfb2b7a40d6801513840285bd684da57b08a537a8161fe2f9c6a22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757442300,
      "headline": "Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System",
      "id": 136689250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.",
      "url": "https://finnhub.io/api/news?id=199769a42edfb2b7a40d6801513840285bd684da57b08a537a8161fe2f9c6a22"
    }
  },
  {
    "ts": null,
    "headline": "Did Boston Scientific's (BSX) Executive Change Signal a New Chapter for Peripheral Interventions Leadership?",
    "summary": "Boston Scientific Corporation recently announced that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire effective December 1, 2025, and serve as a senior advisor until February 27, 2026. This leadership transition marks an important inflection point for the company's Peripheral Interventions division and may prompt discussion about the continuity of strategic direction and operational execution. We'll explore how the upcoming leadership...",
    "url": "https://finnhub.io/api/news?id=b14035d0472c6d7b108d1c8989c13667fea7df7bbdaccf1e682ae044a74d2af3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757425911,
      "headline": "Did Boston Scientific's (BSX) Executive Change Signal a New Chapter for Peripheral Interventions Leadership?",
      "id": 136689251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation recently announced that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire effective December 1, 2025, and serve as a senior advisor until February 27, 2026. This leadership transition marks an important inflection point for the company's Peripheral Interventions division and may prompt discussion about the continuity of strategic direction and operational execution. We'll explore how the upcoming leadership...",
      "url": "https://finnhub.io/api/news?id=b14035d0472c6d7b108d1c8989c13667fea7df7bbdaccf1e682ae044a74d2af3"
    }
  },
  {
    "ts": null,
    "headline": "Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million",
    "summary": "- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitiv",
    "url": "https://finnhub.io/api/news?id=54a93e1019179d48f0972ceec03c01bee5a45b58b61e511a5d70964087b01fa6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757424600,
      "headline": "Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million",
      "id": 136689252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitiv",
      "url": "https://finnhub.io/api/news?id=54a93e1019179d48f0972ceec03c01bee5a45b58b61e511a5d70964087b01fa6"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific to Buy Elutia's Bioenvelope Business for $88M",
    "summary": "Boston Scientific to Buy Elutia's Bioenvelope Business for $88M",
    "url": "https://finnhub.io/api/news?id=77ea1bc0702f838f2d5849897f03a5c331f153329d0da235dfb19f128bd08dec",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757408280,
      "headline": "Boston Scientific to Buy Elutia's Bioenvelope Business for $88M",
      "id": 136714748,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific to Buy Elutia's Bioenvelope Business for $88M",
      "url": "https://finnhub.io/api/news?id=77ea1bc0702f838f2d5849897f03a5c331f153329d0da235dfb19f128bd08dec"
    }
  }
]